Bioresorbable scaffolds (BRSs) represent one of the most promising innovations in the field of coronary intervention in recent memory. In the first trials investigating their use, only simple lesions were included, and the presence of side branches (SB) ≥2 mm were an exclusion criterion [1–3]; therefore, at present BRS implantation in bifurcations is regarded as an off-label practice. On the other hand, the idea of avoiding a permanent metallic cage seems particularly attractive in the case of a bifurcation lesion [4], because: